...
 Why us?  Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

 Author  Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making. Authored and medically reviewed by Dr Farzana Khan.

MD MRCGP DFFP
Was this answer helpful?
Rate Dr Farzana's explanation
faq Vaginal Laxity (postnatalmenopause support)

Who should avoid laser/RF for laxity (pregnancy, implants, infection)?

Energy-based vaginal treatments (laser or radiofrequency) are not for everyone. Defer if you’re pregnant, have an active vaginal infection (BV, thrush, UTI), fever or malodorous discharge, new post-menopausal bleeding, or you’ve had recent pelvic/perineal surgery without clearance. Extra caution is needed with implanted electronic devices, poorly controlled pelvic pain, or suspected prolapse. Foundations—pelvic floor rehab and GSM care—come first. Educational only. Results vary. Not a cure.

Clinical Context

Who is not a candidate right now? Anyone pregnant; with active BV/thrush/UTI; malodorous discharge or fever; new post-menopausal bleeding; recent pelvic/perineal surgery without clearance; poorly controlled pelvic pain; suspected prolapse beyond the introitus; or implanted electronic devices without specialist advice.

Who may be eligible later? Postnatal women after full healing and a supervised pelvic floor block; peri-/post-menopausal women whose mild entry-focused symptoms persist despite excellent GSM care and training. Selection remains careful and goals modest.

Alternatives while you wait. Continue supervised pelvic floor training (activation, long holds 6–10 s, quick squeezes, “the knack”), schedule a vaginal moisturiser 2–4 nights weekly, use a generous compatible lubricant (water-based for versatility/condoms; silicone-based for the longest glide; avoid oil with latex), tidy cough/constipation, and consider scar-aware strategies if relevant.

Evidence-Based Approaches

NHS, patient-friendly foundations: Practical guidance on conservative care—see pelvic floor exercises and GSM-related dryness support at vaginal dryness.

NICE menopause guideline (NG23): Recommends first-line vaginal moisturisers/lubricants and considering low-dose local vaginal oestrogen when symptoms affect quality of life—devices are not routine first-line for GSM or laxity: NICE NG23.

NICE urinary incontinence/prolapse (NG123): Emphasises supervised pelvic floor muscle training first-line and criteria for referral/surgery—principles that underpin selection before procedures: NICE NG123.

Cochrane context: Systematic reviews of vaginal laser/RF highlight small trials, short follow-up and heterogeneity—hence cautious, adjunctive positioning and robust consent/audit: Cochrane Library – vaginal laser/radiofrequency.

Regulatory & safety (UK): UK regulator information on device marking (UKCA/CE), intended use and adverse event reporting supports safe adoption and vigilance: MHRA – medical devices & Yellow Card.

Pathophysiology (peer-reviewed): Overviews of GSM mechanisms explain why friction control and local therapy matter even when procedures are discussed: PubMed – GSM overview.